Plus Therapeutics (NASDAQ:PSTV) Stock Rating Upgraded by Wall Street Zen

Plus Therapeutics (NASDAQ:PSTV) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $1.00 price target (down from $2.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Lake Street Capital assumed coverage on Plus Therapeutics in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 price objective on the stock. Finally, D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.60.

Plus Therapeutics Price Performance

PSTV opened at $3.56 on Friday. The company has a market capitalization of $24.42 million, a P/E ratio of -0.11 and a beta of 1.03. The firm’s fifty day moving average price is $0.39 and its two-hundred day moving average price is $0.50. Plus Therapeutics has a fifty-two week low of $3.23 and a fifty-two week high of $30.50.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.28. The business had revenue of $1.37 million during the quarter, compared to analyst estimates of $1.23 million. On average, equities research analysts expect that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Plus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. L1 Global Manager Pty Ltd acquired a new position in Plus Therapeutics in the fourth quarter valued at about $1,167,000. Jane Street Group LLC acquired a new stake in shares of Plus Therapeutics during the second quarter worth approximately $41,000. Geode Capital Management LLC increased its holdings in shares of Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after buying an additional 589,544 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Plus Therapeutics in the fourth quarter valued at approximately $254,000. Finally, State Street Corp raised its stake in shares of Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after acquiring an additional 127,000 shares during the last quarter. 3.28% of the stock is owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.